Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram

European Neuropsychopharmacology

Volumn 11, Issue 4, 2001, Pages 275-283

  Brosen, Kim ^a   Naranjo, Claudio A ^b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Citalopram; CYP; Interaction; SSRI

Indexed keywords

ALPRAZOLAM; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; CAFFEINE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DESIPRAMINE; DIGOXIN; FLUOXETINE; FLUVOXAMINE; GLYCOPROTEIN P; IMIPRAMINE; MOCLOBEMIDE; NORFLUOXETINE; NORTRIPTYLINE; OMEPRAZOLE; PAROXETINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNINDEXED DRUG; WARFARIN;

BIOTRANSFORMATION; DEPRESSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG METABOLISM; HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; SEROTONIN SYNDROME; TOBACCO;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CITALOPRAM; CYTOCHROMES; DRUG INTERACTIONS; HUMANS; P-GLYCOPROTEIN; SEROTONIN UPTAKE INHIBITORS;

EID: 0034889181     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(01)00101-8     Document Type: Review

References (77)

1. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
2. Lack of desipramine toxicity with citalopram
3. No effect of citalopram on plasma levels of clozapine, risperidone and their active metabolites in patients with chronic schizophrenia
4. 450 CYP1A2 and CYP2C19 hydroxylate melatonin
5. Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study
6. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors
7. The pharmacokinetics of citalopram
8. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation
9. A 'therapeutic window' with citalopram in a case of depression
10. Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram A double-blind comparison of three dose levels
11. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation
12. Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences
13. Citalopram and clozapine: potential drug interaction
14. Clinical significance of the sparteine/debrisoquine oxidation polymorphism
15. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin
16. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6 - the source of the sparteine/debrisoquine oxidation polymorphism
17. The pharmacogenetics of the selective serotonin reuptake inhibitors
18. Fluvoxamine is a potent inhibitor of cytochrome P4501A2
19. Selective serotonin reuptake inhibitors: pharmacokinetics and drug interactions
20. Differences in interactions of SSRIs
21. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?
22. The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6/CYP2D6) activity in human liver microsomes
23. Citalopram - a highly selective 5-HT uptake inhibitor in the treatment of depressed patients
24. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs
25. Serotonin uptake blockers and the treatment of alcoholism
26. Citalopram: interaction studies with levomepromazine, imipramine, and lithium
27. Drug interactions with newer antidepressants: role of human cytochromes P450
28. Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions
29. The S-enantiomer of citalopram (Lu 26-054): cytochromes p450 mediating metabolism and cytochrome inhibitory effects
30. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
31. The serotonergic syndrome: moclobemide and citalopram
32. Lack of effect of a single dose of ketoconazole on the pharmacokinetics of citalopram
33. Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype
34. The pharmacological effect of citaloprom residues in the (S)-(+)-enantiomer
35. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine
36. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes
37. The kinetics of citalopram; single and multiple dose studies in man
38. The effects of citalopram in single and repeated doses and with alcohol on physiological and psychological measures in healthy subjects
39. Lack of adverse interactions between concomitantly administered selegiline and citalopram
40. Lack of citalopram effect on oral digoxin pharmacokinetics
41. Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo
42. Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases
43. The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method
44. Increased serum drug concentrations in concomitant treatment with citalopram, clomipramine and alprazolam
45. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') are attenuated by the serotonin uptake inhibitor citalopram
46. Lack of citalopram-cyclosporine interaction. Abstract
47. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
48. Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide
49. The epidemiology of comorbidity between depression, anxiety disorders and somatic diseases
50. Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects
51. Fatality caused by a combined trimipramine-citalopram intoxication
52. Effect of citalopram on plasma levels of oral theophylline
53. Metabolic interactions of central nervous system medications and selective serotonin reuptake inhibitors
54. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses
55. Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group
56. Lack of interaction between citalopram and the CYP3A4 substrate triazolam [In Process Citation]
57. Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes
58. Pharmacokinetic interaction study of citalopram and cimetidine in healthy subjects
59. Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin
60. CYP2C
61. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reversed-phase liquid chromatography
62. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes
63. Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium
64. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians
65. Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans
66. Multidrug-resistance transporters
67. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms
68. Inhibitors of imipramine metabolism by human liver microsomes
69. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence
70. Combined serotonin syndrome and hyponatraemia caused by a citalopram-buspirone interaction
71. The serotonin syndrome
72. Depression in old age
73. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients
74. Co-administration of citalopram and clozapine: effect on plasma clozapine levels
75. Interaction of fluoxetine with tricyclic antidepressants
76. CYP3A